Welcome to ImmungenX’s
"Behind The Study" Series!
In partnership with Beyond Celiac, ImmunogenX is proud to present this short email series called “Behind the Study," shining light onto what’s involved in their clinical trials for celiac disease and explaining how their investigational medication, latiglutenase, works. The ImmunogenX team believes it is important to support the research and development of new therapies for celiac disease because the celiac community deserves more than just a restrictive diet to live their best life.
ImmunogenX is currently running 2 clinical trials. Click on each logo below to learn more:
To start, let’s introduce ourselves!
You may have heard of us a few times in research news, conferences, webinars, and through our clinical trials. Our company, ImmunogenX, may sound like a big word, but we are actually a small business that was formed to address critical needs for individuals with suspected or diagnosed celiac disease.
Immunology and Genetics
The name ImmunogenX comes from the combination of “immunology” and “genetics”. Celiac disease is, at its core, an autoimmune disorder with a genetic link.
ImmunogenX is woman-owned and patient-led
We are not only fighting for patients with celiac disease, we are led by one!
Jennifer Sealey-Voyksner, PhD, is the co-founder and chief scientific officer (CSO) of ImmunogenX. She was diagnosed with celiac disease nearly 20 years ago.
Since then, she has gone through the same trials and tribulations as any celiac disease patient: adjusting her lifestyle, food choices, and social interactions to protect her health. These experiences strengthen her resolve to improve the quality of life for patients with celiac disease like herself. Through ImmunogenX, she works toward finding solutions that improve the lives of patients in the celiac community.
Driving Latiglutenase to the Finish Line
In close collaboration with the National Institutes of Health (NIH) and leading physician-researchers, we look forward to completing our ongoing trials followed by launching our phase 3 program, and completing the regulatory approval process – all in order to bring latiglutenase* to the patients who need it.
If you would like to get involved, you can learn more about our studies by visiting ImmunogenX.com/patients Or by visiting our study sites directly:
Solutions for Celiac (Nationwide) email@example.com
Diabetes+Celiac Research Study (Northern California) firstname.lastname@example.org
*Latiglutenase has not yet been approved by the FDA and is limited to investigational use only.
This article was originally published in Beyond Celiac's email newsletter on Nov 3, 2021.